Rozenn Quarck

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6364279/publications.pdf

Version: 2024-02-01

		186209	223716
58	2,581	28	46
papers	citations	h-index	g-index

58	58	58	3294
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Residential air pollution increases the risk for persistent pulmonary hypertension after pulmonary endarterectomy. European Respiratory Journal, 2021, 57, 2002680.	3.1	3
2	Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload. Cardiovascular Research, 2021, 117, 2474-2488.	1.8	20
3	Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry. ERJ Open Research, 2021, 7, 00850-2020.	1.1	65
4	Incremental Experience in In Vitro Primary Culture of Human Pulmonary Arterial Endothelial Cells Harvested from Swan-Ganz Pulmonary Arterial Catheters. Cells, 2021, 10, 3229.	1.8	2
5	COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey. ERJ Open Research, 2020, 6, 00520-2020.	1.1	40
6	Î±1AMP-Activated Protein Kinase Protects against Lipopolysaccharide-Induced Endothelial Barrier Disruption via Junctional Reinforcement and Activation of the p38 MAPK/HSP27 Pathway. International Journal of Molecular Sciences, 2020, 21, 5581.	1.8	9
7	CCR2/CCR5-mediated macrophageâ€“smooth muscle cell crosstalk in pulmonary hypertension. European Respiratory Journal, 2019, 54, 1802308.	3.1	73
8	Cytokines trigger disruption of endothelium barrier function and p38ÂMAP kinase activation in BMPR2â€silenced human lung microvascular endothelial cells. Pulmonary Circulation, 2019, 9, 1-13.	0.8	12
9	Doubleâ€lung versus heartâ€lung transplantation for precapillary pulmonary arterial hypertension: a 24â€year singleâ€center retrospective study. Transplant International, 2019, 32, 717-729.	0.8	29
10	Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations. European Respiratory Review, 2019, 28, 190050.	3.0	39
11	TGFÎ² and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension. Drug Discovery Today, 2019, 24, 703-716.	3.2	64
12	Late Breaking Abstract - Development of an animal model for group 3 Pulmonary Hypertension. , 2018, , .		1
13	Targeting CCR2 and CCR5 to inhibit macrophage/pulmonary artery smooth muscle cells cross-talk in pulmonary hypertension. , 2018, , .		0
14	Activation of the Beta-3 adrenoceptor in experimental pulmonary hypertension. , 2018, , .		0
15	Local inhibition of angiogenesis combined with repeated blood clot embolization induces chronic thromboembolic pulmonary hypertension in rabbits. , 2018, , .		0
16	Effect of BMPRII on endothelial function in human lung microvascular endothelial cells. , 2018, , .		0
17	Rescuing BMPR2-driven endothelial dysfunction in PAH: a novel treatment strategy for the future?. Stem Cell Investigation, 2017, 4, 56-56.	1.3	8
18	Impact of insomnia on exercise capacity and quality of life in patients with pulmonary arterial hypertension. , 2017, , .		0

#	Article	IF	Citations
19	Administration of mitomycin results in pulmonary hypertension and vascular remodeling in rabbits. , 2017, , .		0
20	Progressive Vascular Functional and Structural Damage in a Bronchopulmonary Dysplasia Model in Preterm Rabbits Exposed to Hyperoxia. International Journal of Molecular Sciences, 2016, 17, 1776.	1.8	28
21	Extracellular Calpain/Calpastatin Balance Is Involved in the Progression of Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 337-351.	1.4	21
22	Letter by Belge et al Regarding Article, â€œMitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Modelsâ€• Circulation, 2016, 133, e591.	1.6	4
23	Osteopontin, a Key Mediator Expressed by Senescent Pulmonary Vascular Cells in Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1879-1890.	1.1	46
24	Role of interleukin-1 receptor 1/MyD88 signalling in the development and progression of pulmonary hypertension. European Respiratory Journal, 2016, 48, 470-483.	3.1	79
25	BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators. Pflugers Archiv European Journal of Physiology, 2016, 468, 1969-1983.	1.3	20
26	IL18 induces p38 MAP kinase activation and adhesion capacities in BMPRII knocked down human lung microvascular endothelial cells. , 2016, , .		0
27	Role for Telomerase in Pulmonary Hypertension. Circulation, 2015, 131, 742-755.	1.6	36
28	Chemotherapy-Induced Pulmonary Hypertension. American Journal of Pathology, 2015, 185, 356-371.	1.9	149
29	Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2015, 46, 431-443.	3.1	127
30	Chemotherapy-induced pulmonary hypertension: Role of alkylating agents. , 2015, , .		3
31	CCR5 as a Treatment Target in Pulmonary Arterial Hypertension. Circulation, 2014, 130, 880-891.	1.6	64
32	Is inflammation a potential therapeutic target in chronic thromboembolic pulmonary hypertension?. European Respiratory Journal, 2014, 44, 842-845.	3.1	4
33	Amorphous Silica Nanoparticles Promote Monocyte Adhesion to Human Endothelial Cells: Sizeâ€Đependent Effect. Small, 2013, 9, 430-438.	5.2	36
34	NF-Î²B pathway is involved in CRP-induced effects on pulmonary arterial endothelial cells in chronic thromboembolic pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2013, 305, L934-L942.	1.3	36
35	Measurement of right ventricular pressure by telemetry in conscious moving rabbits. Laboratory Animals, 2013, 47, 184-193.	0.5	7
36	Effects of C-reactive protein on human pulmonary vascular cells in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2012, 40, 886-894.	3.1	74

#	Article	IF	Citations
37	Characterization of proximal pulmonary arterial cells from chronic thromboembolic pulmonary hypertension patients. Respiratory Research, 2012, 13, 27.	1.4	41
38	C-reactive Protein Contributes To Pulmonary Vascular Cell Dysfunction In Chronic Thromboembolic Pulmonary Hypertension. , 2010, , .		0
39	Role Of Endothelial And Smooth Muscle Cells In Vascular Wall Remodeling Of Large Pulmonary Arteries In Patients With CTEPH. , 2010, , .		0
40	C-Reactive Protein. Journal of the American College of Cardiology, 2009, 53, 1211-1218.	1.2	220
41	Markers of inflammation and disuse in vastus lateralis of chronic obstructive pulmonary disease patients. European Journal of Clinical Investigation, 2007, 37, 897-904.	1.7	103
42	Effect of adenovirus-mediated gene transfer of nitric oxide synthase on vascular reactivity of rat isolated pulmonary arteries. Pflugers Archiv European Journal of Physiology, 2006, 452, 213-221.	1.3	6
43	Human Paraoxonase-1 Overexpression Inhibits Atherosclerosis in a Mouse Model of Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1545-1550.	1.1	157
44	Weight Lossâ€“Associated Induction of Peroxisome Proliferatorâ€“Activated Receptor-Î± and Peroxisome Proliferatorâ€“Activated Receptor-Î³ Correlate With Reduced Atherosclerosis and Improved Cardiovascular Function in Obese Insulin-Resistant Mice. Circulation, 2004, 110, 3259-3269.	1.6	121
45	Gene Therapy Approaches for Cardiovascular Diseases. Current Gene Therapy, 2004, 4, 207-223.	0.9	23
46	Increased Low-Density Lipoprotein Oxidation and Impaired High-Density Lipoprotein Antioxidant Defense Are Associated With Increased Macrophage Homing and Atherosclerosis in Dyslipidemic Obese Mice. Circulation, 2003, 107, 1640-1646.	1.6	166
47	Dietary cholesterol withdrawal reduces vascular inflammation and induces coronary plaque stabilization in miniature pigs. Cardiovascular Research, 2002, 56, 135-144.	1.8	58
48	Hypercholesterolemia impairs vascular remodelling after porcine coronary angioplasty. Cardiovascular Research, 2002, 55, 385-395.	1.8	26
49	Identification of the phospholipase A2 isoforms that contribute to arachidonic acid release in hypoxic endothelial cells: limits of phospholipase A2 inhibitors. Biochemical Pharmacology, 2002, 63, 321-332.	2.0	33
50	Restenosis and gene therapy. Expert Opinion on Biological Therapy, 2001, 1, 79-91.	1.4	11
51	Adenovirus-Mediated Gene Transfer of Human Platelet-Activating Factorâ€“Acetylhydrolase Prevents Injury-Induced Neointima Formation and Reduces Spontaneous Atherosclerosis in Apolipoprotein Eâ€“Deficient Mice. Circulation, 2001, 103, 2495-2500.	1.6	197
52	Arg123-Tyr166 Domain of Human ApoA-I Is Critical for HDL-Mediated Inhibition of Macrophage Homing and Early Atherosclerosis in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1977-1983.	1.1	50
53	Transforming growth factor Î² 1 inhibits mitogen-activated protein kinase induced by basic fibroblast growth factor in smooth muscle cells. Biochemical Journal, 1996, 316, 167-173.	1.7	28
54	Smooth Muscle Cell Cycle and Proliferation. Journal of Biological Chemistry, 1996, 271, 27788-27794.	1.6	97

#	Article	IF	Citations
55	Abnormal cAMP-induced phosphorylation of rap 1, protein in grey platelet syndrome platelets. British Journal of Haematology, 1994, 86, 338-346.	1.2	8
56	Ultrastructural localization of the small GTPâ€binding protein Rap 1 in human platelets and megakaryocytes. British Journal of Haematology, 1994, 88, 372-382.	1.2	42
57	The rat platelet 97-kDa Ca2+ATPase isoform is the sarcoendoplasmic reticulum Ca2+ATPase 3 protein. Journal of Biological Chemistry, 1994, 269, 1417-24.	1.6	95
58	Health effects of exposure to residential air pollution in patients with pulmonary arterial hypertension: A cohort study in Belgium. European Respiratory Journal, 0, , 2102335.	3.1	0